Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials

Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult. Systemic chemotherapy has been an established part of the standard t...

Full description

Bibliographic Details
Main Authors:	Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Current Oncology
Subjects:	pancreatic adenocarcinoma radiotherapy chemoradiation stereotactic body radiation therapy ablative radiotherapy MR-guided radiation therapy
Online Access:	https://www.mdpi.com/1718-7729/30/7/499

Similar Items

The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer
by: Shyama U. Tetar, et al.
Published: (2020-09-01)

Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center
by: Liang-Cheng Chen, et al.
Published: (2021-01-01)

Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia
by: Berend J. Slotman, et al.
Published: (2022-08-01)

MR‐Linac guided adaptive stereotactic ablative body radiotherapy for recurrent cardiac sarcoma with mitral valve bioprosthesis – a case report
by: Vikneswary Batumalai, et al.
Published: (2023-06-01)

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
by: Mix M, et al.
Published: (2019-12-01)

Editorial: New Approaches to Breast Cancer Radiotherapy
by: Geraldine Meerbott Jacobson, et al.
Published: (2021-02-01)

Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
by: C.A. Fink, et al.
Published: (2024-05-01)

Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors
by: Atalar Banu, et al.
Published: (2020-06-01)

Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases
by: Gamze Ugurluer, et al.
Published: (2024-05-01)

Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer
by: Christoph A. Fink, et al.
Published: (2024-02-01)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
by: Noura Radwan, et al.
Published: (2017-06-01)

Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases
by: Paul B. Romesser, et al.
Published: (2021-04-01)

Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
by: Kristiina Vuolukka, et al.
Published: (2020-07-01)

Tumor-site specific geometric distortions in high field integrated magnetic resonance linear accelerator radiotherapy
by: Signe Winther Hasler, et al.
Published: (2020-07-01)

Training and Validation of Deep Learning-Based Auto-Segmentation Models for Lung Stereotactic Ablative Radiotherapy Using Retrospective Radiotherapy Planning Contours
by: Jordan Wong, et al.
Published: (2021-06-01)

Ocular Complications of Radiotherapy in Uveal Melanoma
by: Mihail Zemba, et al.
Published: (2023-01-01)

Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: A multicentric retrospective study from the French group COLib
by: J. Chamois, et al.
Published: (2024-05-01)

Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)
by: Alessandra Arcelli, et al.
Published: (2020-11-01)

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
by: Rohit K. Raj, et al.
Published: (2023-12-01)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
by: Robert Olson, et al.
Published: (2018-10-01)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
by: Berber T, et al.
Published: (2022-08-01)

Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer
by: Robert eMeier
Published: (2015-04-01)

Long-Term Clinical Results of MR-Guided Stereotactic Body Radiotherapy of Liver Metastases
by: Fabian Weykamp, et al.
Published: (2023-05-01)

Proposal and Evaluation of a Physician-Free, Real-Time On-Table Adaptive Radiotherapy (PF-ROAR) Workflow for the MRIdian MR-Guided LINAC
by: Jacob C. Ricci, et al.
Published: (2022-02-01)

Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases
by: Fabian Weykamp, et al.
Published: (2022-12-01)

Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis
by: Po-Lung Cheng, et al.
Published: (2023-04-01)

Organizing pneumonia after stereotactic ablative radiotherapy of the lung
by: Murai Taro, et al.
Published: (2012-08-01)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
by: Bin Qiu, et al.
Published: (2020-08-01)

Selection of motion management in liver stereotactic body radiotherapy and its impact on treatment time
by: Nicholas Hardcastle, et al.
Published: (2023-01-01)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
by: Seth R. Blacksburg, et al.
Published: (2020-12-01)

Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases
by: Geoffrey Martinage, et al.
Published: (2019-03-01)

Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions
by: John Michael Bryant, et al.
Published: (2023-03-01)

MR-guided stereotactic radiation therapy for head and neck cancers
by: He Wang, et al.
Published: (2024-05-01)

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer
by: Francesco Cuccia, et al.
Published: (2021-04-01)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
by: James J. Biagi, et al.
Published: (2023-07-01)

Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1)
by: Alessandra Arcelli, et al.
Published: (2023-06-01)

Complications from Stereotactic Body Radiotherapy for Lung Cancer
by: Kylie H. Kang, et al.
Published: (2015-06-01)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
by: Maria L. Sandoval, MD, MS, et al.
Published: (2023-05-01)

Editorial: Novel Applications of Stereotactic Body Radiotherapy (SBRT)
by: Rupesh Kotecha, et al.
Published: (2021-09-01)

An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
by: Izabela Zarębska, et al.
Published: (2023-10-01)